应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02410 同源康医药-B
已收盘 04-22 16:08:12
28.000
+0.700
+2.56%
最高
28.500
最低
26.600
成交量
153.88万
今开
27.100
昨收
27.300
日振幅
6.96%
总市值
103.88亿
流通市值
102.48亿
总股本
3.71亿
成交额
4,241万
换手率
0.42%
流通股本
3.66亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
同源康医药-B04月16日获主力加仓2008万元
市场透视 · 04-16
同源康医药-B04月16日获主力加仓2008万元
港股异动 | 同源康医药-B(02410)尾盘涨超6% TY-9591入选ASCO本土创新药企实现技术突破
智通财经网 · 04-16
港股异动 | 同源康医药-B(02410)尾盘涨超6% TY-9591入选ASCO本土创新药企实现技术突破
同源康医药-B04月14日主力净流出79万元 散户资金买入
市场透视 · 04-14
同源康医药-B04月14日主力净流出79万元 散户资金买入
同源康医药-B盘中异动 急速下跌5.20%报33.700港元
市场透视 · 03-11
同源康医药-B盘中异动 急速下跌5.20%报33.700港元
“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物
钛媒体 · 03-10
“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物
“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%
澎湃 · 03-10
“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%
关键临床数据达到研究预期，同源康医药-B(02410)展现高值潜力
智通财经 · 03-10
关键临床数据达到研究预期，同源康医药-B(02410)展现高值潜力
同源康医药(02410)关键临床达预期 股价早盘一度大涨50.65%
金吾财讯 · 03-10
同源康医药(02410)关键临床达预期 股价早盘一度大涨50.65%
港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期
智通财经 · 03-10
港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期
深交所发布关于深港通下的港股通标的证券名单调整的公告
深交所网站 · 03-10
深交所发布关于深港通下的港股通标的证券名单调整的公告
智通港股早知道 | 港股今年日均成交额超2000亿港元 3月组件排产提升显著
智通财经 · 03-09
智通港股早知道 | 港股今年日均成交额超2000亿港元 3月组件排产提升显著
【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。
金融界 · 03-09
【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。
同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益
智通财经 · 03-09
同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益
同源康医药-B03月07日获主力加仓930万元
市场透视 · 03-07
同源康医药-B03月07日获主力加仓930万元
同源康医药-B盘中异动 临近午盘股价大涨5.58%报31.200港元
市场透视 · 03-07
同源康医药-B盘中异动 临近午盘股价大涨5.58%报31.200港元
同源康医药-B盘中异动 下午盘股价大跌6.45%报29.000港元
市场透视 · 03-06
同源康医药-B盘中异动 下午盘股价大跌6.45%报29.000港元
同源康医药-B盘中异动 早盘大幅下挫5.63%报30.200港元
市场透视 · 03-05
同源康医药-B盘中异动 早盘大幅下挫5.63%报30.200港元
同源康医药-B盘中异动 快速跳水7.26%报30.000港元
市场透视 · 03-03
同源康医药-B盘中异动 快速跳水7.26%报30.000港元
同源康医药-B盘中异动 早盘大幅跳水6.40%报28.500港元
市场透视 · 02-28
同源康医药-B盘中异动 早盘大幅跳水6.40%报28.500港元
加载更多
公司概况
公司名称：
同源康医药-B
所属市场：
SEHK
上市日期：
--
主营业务：
浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。
发行价格：
--
{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":28,"timestamp":1745309292015,"preClose":27.3,"halted":0,"volume":1538750,"delay":0,"floatShares":366000000,"shares":371000000,"eps":-1.2156501914073405,"marketStatus":"已收盘","change":0.7,"latestTime":"04-22 16:08:12","open":27.1,"high":28.5,"low":26.6,"amount":42414762,"amplitude":0.069597,"askPrice":28.1,"askSize":1500,"bidPrice":27.6,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.2156501914073405,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":5,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":27.3,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":0.784356,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02410","defaultTab":"news","newsList":[{"id":"2527264712","title":"同源康医药-B04月16日获主力加仓2008万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527264712","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527264712?lang=zh_cn&edition=full","pubTime":"2025-04-16 16:16","pubTimestamp":1744791411,"startTime":"0","endTime":"0","summary":"04月16日, 同源康医药-B股价涨4.97%，报收27.45元，成交金额7017万元，换手率0.73%，振幅10.71%，量比1.94。同源康医药-B今日主力资金净流入2008万元，上一交易日主力净流入101万元。该股近5个交易日上涨4.61%，主力资金累计净流入3538万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.37亿元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416174030a45aec28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416174030a45aec28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","BK1161","09939","02410"],"gpt_icon":0},{"id":"2527325671","title":"港股异动 | 同源康医药-B(02410)尾盘涨超6% TY-9591入选ASCO本土创新药企实现技术突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2527325671","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527325671?lang=zh_cn&edition=full","pubTime":"2025-04-16 15:20","pubTimestamp":1744788000,"startTime":"0","endTime":"0","summary":"同源康医药-B尾盘涨超6%，截至发稿，涨5.54%，报57.6港元，成交额4703.9万港元。消息面上，2025年美国临床肿瘤学会年会将于2025年5月30日至6月3日于美国芝加哥举行。同源康医药核心产品TY-9591的最新研究成果也入选2025年美国临床肿瘤学会大会报告。这是TY-9591首次亮相ASCO大会，并荣获口头报告。由于出色的关键II期临床试验结果，TY-9591有望成为全球第一个获批脑转移适应症的三代EGFR抑制剂。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-16/doc-inetiwey0209077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","09939","02410","TY","BK1161","159938","BK1515","BK1574"],"gpt_icon":0},{"id":"2527476137","title":"同源康医药-B04月14日主力净流出79万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527476137","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527476137?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:17","pubTimestamp":1744618644,"startTime":"0","endTime":"0","summary":"04月14日, 同源康医药-B股价跌2.04%，报收26.45元，成交金额3225万元，换手率0.33%，振幅4.63%，量比0.74。同源康医药-B今日主力资金净流出79万元，上一交易日主力净流入1187万元。该股近5个交易日上涨0.19%，主力资金累计净流入1310万元；近20日主力资金累计净流入2.14亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171644a6b9dcb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171644a6b9dcb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","BK1574","02410","09939"],"gpt_icon":0},{"id":"2518340927","title":"同源康医药-B盘中异动 急速下跌5.20%报33.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518340927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518340927?lang=zh_cn&edition=full","pubTime":"2025-03-11 09:33","pubTimestamp":1741656782,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘09时33分，同源康医药-B股票出现异动，股价快速下挫5.20%。截至发稿，该股报33.700港元/股，成交量3.25万股，换手率0.01%，振幅5.34%。资金方面，该股资金流入7.0875万港元，流出61.395万港元。同源康医药-B股票所在的生物技术行业中，整体跌幅为0.08%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。TY-2136b为自主研发、口服ROS1/NTRK抑制剂,用于治疗实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093302abf4841b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093302abf4841b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","02410","BK1574","BK1515"],"gpt_icon":0},{"id":"2518980270","title":"“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2518980270","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518980270?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:00","pubTimestamp":1741622432,"startTime":"0","endTime":"0","summary":"同源康医药计划于近期提交卡达沙的NDA上市申请。根据同源康医药招股书介绍，卡达沙有两大单药研究方向：一是EGFR突变NSCLC脑转移，即癌细胞从其原发部位扩散到大脑，这一适应症目前尚无专属获批药物。目前，同源康医药公布了该实验的积极“头对头”数据。可见，同源康药业选择的小众赛道上，也不乏更多追赶者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100003998a2bcda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100003998a2bcda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","09939","BK1574","BK1161","02410"],"gpt_icon":0},{"id":"2518527194","title":"“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518527194","media":"澎湃","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518527194?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:18","pubTimestamp":1741616326,"startTime":"0","endTime":"0","summary":"同源康医药 视觉中国 资料图3月10日，浙江同源康医药股份有限公司早盘最高涨超50%，收涨16.18%。同源康医药称，针对EGFR突变肺癌脑转移适应证，TY-9591是全球首个且唯一单药头对头奥希替尼临床研究中显示出显著优于奥希替尼的药物。“头对头”挑战这一重磅品种，同源康医药最新的积极数据自然引发全行业关注。官网资料显示，同源康医药成立于2017年11月，2024年8月在港股上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223049abf31290&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223049abf31290&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1515","BK1161","02410"],"gpt_icon":0},{"id":"2518864264","title":"关键临床数据达到研究预期，同源康医药-B(02410)展现高值潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2518864264","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518864264?lang=zh_cn&edition=full","pubTime":"2025-03-10 13:33","pubTimestamp":1741584788,"startTime":"0","endTime":"0","summary":"2017 年至 2024 年，中国肺癌脑转移的新患者人数从13.76 万增至17.14 万，预计肺癌脑转移的新患者人数于2033 年将接近22 万，展现国内该治疗市场的广阔前景。此次同源康医药-B公布的旗下 TY-9591 的关键 II 期临床试验研究者数据显示达到研究预期，将成为第三家在头对头试验中展现更优疗效的本土药企。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","BK1161","09939","02410","BK1574"],"gpt_icon":0},{"id":"2518252573","title":"同源康医药(02410)关键临床达预期 股价早盘一度大涨50.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518252573","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518252573?lang=zh_cn&edition=full","pubTime":"2025-03-10 10:39","pubTimestamp":1741574389,"startTime":"0","endTime":"0","summary":"早盘股价表现亮眼，一度大幅抽升50.65%，至46.1港元，随后升幅有所回落，目前暂升26.47%，报38.7港元。此次备受关注的是公司自主研发的TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验。鉴于此次临床试验的积极结果，同源康医药计划在近期向国家药品监督管理局药品审评中心提交新药上市申请。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NTRmYzVmNDdmYzg0MjRhYWE5NzljZDI3ZDUxMDYzNjE2NzY4MDQ=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTRmYzVmNDdmYzg0MjRhYWE5NzljZDI3ZDUxMDYzNjE2NzY4MDQ=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954677","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","159938","02410","BK1161","BK1574"],"gpt_icon":0},{"id":"2518255540","title":"港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518255540","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518255540?lang=zh_cn&edition=full","pubTime":"2025-03-10 09:34","pubTimestamp":1741570495,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B早盘一度涨超40%，截至发稿，涨36.93%，报41.9港元，成交额330万港元。消息面上，3月9日，同源康医药-B发布公告，公司自主研发的TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。公司计划于近期向国家药品监督管理局药品审评中心提交NDA上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1141","09939","02410","BK1574","03347","159938","BK1576","TY","BK1583","BK1161"],"gpt_icon":0},{"id":"2518258529","title":"深交所发布关于深港通下的港股通标的证券名单调整的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2518258529","media":"深交所网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518258529?lang=zh_cn&edition=full","pubTime":"2025-03-10 08:58","pubTimestamp":1741568314,"startTime":"0","endTime":"0","summary":"因恒生综合大型股指数、中型股指数、小型股指数实施成份股定期调整,根据《深圳证券交易所深港通业务实施办法》的有关规定，港股通标的证券名单发生调整并自2025年03月10日起生效，相关调整信息如下：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02506","02586","00743","02105","03939","01318","HSCEI","02522","02407","01541","03650","06639","02577","02507","03669","02582","01468","02431","01799","02432","02460","02799","09959","00095","02121","BK1582","06660","02678","01119","02232","01942","BK1555","06698","02461","02171","06623","02570","00308","02562","01268","02587","02411","00999","HSTECH","09966","02510","01600","00697","00659","09869","02423","BK1240","00041","02410","03309","02487","02150","09985","00410"],"gpt_icon":0},{"id":"2518923180","title":"智通港股早知道 | 港股今年日均成交额超2000亿港元 3月组件排产提升显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2518923180","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518923180?lang=zh_cn&edition=full","pubTime":"2025-03-10 06:59","pubTimestamp":1741561142,"startTime":"0","endTime":"0","summary":"陈翊庭：港股今年以来日均成交额超2000亿港元港交所行政总裁陈翊庭9日表示，港股今年以来日均成交额超2000亿港元。陈翊庭说，港股成交额在过去一年也有很大进步，由2023年平均每日成交额大约1000亿港元升至去年的1320亿港元，今年暂时已突破2000亿港元。她说，今年2月，港股每日成交金额有3次突破4000亿港元，其中很大部分来自世界各地的投资者。涉及港股 港交所及优质券商板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","BK1227","BK4614","BK1594","09969","BK1574","01208","HSTECH","HSCEI","BK1161","02410","BK1190","BK1592"],"gpt_icon":1},{"id":"2518684402","title":"【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518684402","media":"金融界","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518684402?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:12","pubTimestamp":1741518744,"startTime":"0","endTime":"0","summary":"同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/09191248615055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1515","BK1161","TY","BK1574","BK1583","03347","09939","BK1576","BK1141","02410"],"gpt_icon":0},{"id":"2518440289","title":"同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440289","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440289?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:07","pubTimestamp":1741518432,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。公司计划于近期向国家药品监督管理局药品审评中心(CDE)提交NDA (New Drug Application)上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1141","02410","TY","BK1515","09939","159938","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2517095461","title":"同源康医药-B03月07日获主力加仓930万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517095461","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517095461?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:16","pubTimestamp":1741335402,"startTime":"0","endTime":"0","summary":"03月07日, 同源康医药-B股价涨3.55%，报收30.60元，成交金额2440万元，换手率0.22%，振幅15.40%，量比0.77。同源康医药-B今日主力资金净流入930万元，上一交易日主力净流入17万元。该股近5个交易日下跌5.41%，主力资金累计净流出419万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2522万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170707abecc8e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170707abecc8e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","02410","BK1574","BK1515"],"gpt_icon":0},{"id":"2517123724","title":"同源康医药-B盘中异动 临近午盘股价大涨5.58%报31.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517123724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517123724?lang=zh_cn&edition=full","pubTime":"2025-03-07 11:47","pubTimestamp":1741319271,"startTime":"0","endTime":"0","summary":"2025年03月07日临近午盘11时47分，同源康医药-B股票出现波动，股价急速上涨5.58%。截至发稿，该股报31.200港元/股，成交量26.25万股，换手率0.07%，振幅9.48%。资金方面，该股资金流入716.378万港元，流出64.575万港元。同源康医药-B股票所在的生物技术行业中，整体涨幅为0.48%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。TY-2136b为自主研发、口服ROS1/NTRK抑制剂,用于治疗实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307114751989f5b70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307114751989f5b70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","09939","02410","BK1574"],"gpt_icon":0},{"id":"2517186478","title":"同源康医药-B盘中异动 下午盘股价大跌6.45%报29.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517186478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517186478?lang=zh_cn&edition=full","pubTime":"2025-03-06 14:23","pubTimestamp":1741242194,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘14时23分，同源康医药-B股票出现波动，股价急速跳水6.45%。截至发稿，该股报29.000港元/股，成交量39.85万股，换手率0.11%，振幅9.52%。资金方面，该股资金流入665.168万港元，流出549.195万港元。同源康医药-B股票所在的生物技术行业中，整体涨幅为0.51%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306142314abeada0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306142314abeada0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","BK1574","02410","09939"],"gpt_icon":0},{"id":"2517093250","title":"同源康医药-B盘中异动 早盘大幅下挫5.63%报30.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517093250","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517093250?lang=zh_cn&edition=full","pubTime":"2025-03-05 09:42","pubTimestamp":1741138937,"startTime":"0","endTime":"0","summary":"2025年03月05日早盘09时42分，同源康医药-B股票出现异动，股价急速下跌5.63%。截至发稿，该股报30.200港元/股，成交量2.85万股，换手率0.01%，振幅10.31%。资金方面，该股资金流入6.6225万港元，流出68.6275万港元。同源康医药-B股票所在的生物技术行业中，整体涨幅为1.12%。其相关个股中，康宁杰瑞制药-B、和誉-B、再鼎医药涨幅较大，振幅较大的相关个股有同源康医药-B、康宁杰瑞制药-B、和誉-B，振幅分别为9.38%、9.16%、8.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503050942179639f689&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503050942179639f689&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1515","BK1161","02410"],"gpt_icon":0},{"id":"2516524270","title":"同源康医药-B盘中异动 快速跳水7.26%报30.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516524270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516524270?lang=zh_cn&edition=full","pubTime":"2025-03-03 09:40","pubTimestamp":1740966028,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时40分，同源康医药-B股票出现波动，股价快速跳水7.26%。截至发稿，该股报30.000港元/股，成交量8500股，换手率0.00%，振幅7.26%。资金方面，该股资金流入1.5425万港元，流出18.54万港元。同源康医药-B股票所在的生物技术行业中，整体涨幅为0.23%。其相关个股中，北海康成-B、圣诺医药-B、科济药业-B涨幅较大，振幅较大的相关个股有创胜集团-B、永泰生物-B、腾盛博药-B，振幅分别为12.24%、11.31%、8.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303094028abe53645&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303094028abe53645&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1161","BK1515","02410"],"gpt_icon":0},{"id":"2514369057","title":"同源康医药-B盘中异动 早盘大幅跳水6.40%报28.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514369057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514369057?lang=zh_cn&edition=full","pubTime":"2025-02-28 09:48","pubTimestamp":1740707314,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时48分，同源康医药-B股票出现异动，股价快速跳水6.40%。截至发稿，该股报28.500港元/股，成交量1.25万股，换手率0.00%，振幅8.21%。资金方面，该股资金流入9.3万港元，流出28.1825万港元。同源康医药-B股票所在的生物技术行业中，整体涨幅为2.91%。其相关个股中，百济神州、正大企业国际、华昊中天医药-B涨幅较大，振幅较大的相关个股有科笛-B、腾盛博药-B、永泰生物-B，振幅分别为14.18%、12.44%、10.40%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228094834963340a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228094834963340a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1161","09939","BK1515","BK1574"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0282},{"period":"1month","weight":0.0037},{"period":"3month","weight":0.3858},{"period":"6month","weight":-0.1777},{"period":"1year","weight":1.2562},{"period":"ytd","weight":-0.421}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}